For patients receiving PD‐1/PD‐L1 inhibitors, current large randomized clinical trials have not shown any increased risk of infection.10, 11, 12, 13, 14, 15, 16 However, patients may require immunosuppressants such as corticosteroids, TNF‐α targeted agents when irAEs occur, possibly leading to opportunistic infections. The gene discussed is TNF; the disease is infection.